Population Pharmacokinetics and Pharmacodynamics of Burosumab in Adult and Pediatric Patients With X‐linked Hypophosphatemia

Burosumab is a fully human monoclonal antibody against fibroblast growth factor 23, which has been approved to treat X‐linked hypophosphatemia (XLH) in adult and pediatric patients. The present work describes the pharmacokinetics (PK) of burosumab and the pharmacokinetic‐pharmacodynamic (PK‐PD) rela...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Sun Ku, Gosselin, Nathalie H., Taylor, Julie, Roberts, Mary Scott, McKeever, Kathleen, Shi, Jack
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Pharmacometrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292737/
https://www.ncbi.nlm.nih.gov/pubmed/34352114
http://dx.doi.org/10.1002/jcph.1950

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292737/
https://www.ncbi.nlm.nih.gov/pubmed/34352114
http://dx.doi.org/10.1002/jcph.1950

Ejemplares similares